MedTrace Logo

Study of AT-752 in Patients With Dengue Infection

NCT05466240 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-03-05

Study results available
· View outcomes & findings →

Summary

The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials

Conditions

  • Dengue Fever

Interventions

DRUG

AT-752

AT-752 for 5 days

DRUG

Placebo

Placebo for 5 days

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-29
Primary Completion
2023-01-19
Completion
2023-01-19
FDA Drug
Yes

Countries

  • Brazil
  • Colombia
  • Ecuador
  • India
  • Malaysia
  • Peru
  • Philippines
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05466240 on ClinicalTrials.gov